Literature DB >> 14759346

HIV Dementia.

Avindra Nath1, Joseph Berger.   

Abstract

Dementia and milder forms of cognitive impairment are important manifestations, with important socioeconomic consequences, of HIV infection. Early detection and aggressive treatment are essential to achieve stabilization and prevent progression. In some affected individuals, reversal of symptoms may follow initiation of effective therapy. Antiretroviral treatment needs to be individualized, taking into consideration the relative central nervous system penetration of the drugs, presence of drug resistant viral strains, possible drug interactions, and drug side effect profiles. Combination antiretroviral therapy is preferred. Zidovudine, stavudine, abacavir, navirapine and indinavir have relatively good penetration into the central nervous system. The aim of therapy should be for control of viral load in the periphery and the cerebrospinal fluid. Furthermore, although not established therapy, the use of neuroprotective agents and anti-inflammatory regimens may be considered. A comprehensive multidisciplinary approach to management with regular follow-up is essential for treatment.

Entities:  

Year:  2004        PMID: 14759346     DOI: 10.1007/s11940-004-0023-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  77 in total

1.  Assessment of neuronal density in the putamen in human immunodeficiency virus (HIV) infection. Application of stereology and spatial analysis of quadrats.

Authors:  I Everall; H Barnes; E Spargo; P Lantos
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

2.  Variable progression of HIV-associated dementia.

Authors:  F H Bouwman; R L Skolasky; D Hes; O A Selnes; J D Glass; T E Nance-Sproson; W Royal; G J Dal Pan; J C McArthur
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 3.  The AIDS dementia complex.

Authors:  R W Price; B J Brew
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

4.  Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.

Authors:  R W Price; C T Yiannoutsos; D B Clifford; L Zaborski; A Tselis; J J Sidtis; B Cohen; C D Hall; A Erice; K Henry
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

Review 5.  Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1.

Authors:  Robert Paul; Ronald Cohen; Bradford Navia; Karen Tashima
Journal:  Neurosci Biobehav Rev       Date:  2002-05       Impact factor: 8.989

6.  New onset seizures in HIV-infected patients without intracranial mass lesions or meningitis--a clinical, radiological and SPECT scan study.

Authors:  Girish Modi; Mala Modi; Ighsan Martinus; Mboyo Vangu
Journal:  J Neurol Sci       Date:  2002-10-15       Impact factor: 3.181

7.  The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection.

Authors:  B A Navia; R W Price
Journal:  Arch Neurol       Date:  1987-01

Review 8.  The role of the blood-brain barrier in HIV infection of the central nervous system.

Authors:  A A Hurwitz; J W Berman; W D Lyman
Journal:  Adv Neuroimmunol       Date:  1994

9.  HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times.

Authors:  J Laubenberger; D Häussinger; S Bayer; S Thielemann; B Schneider; A Mundinger; J Hennig; M Langer
Journal:  Radiology       Date:  1996-06       Impact factor: 11.105

10.  Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.

Authors:  N M Graham; D R Hoover; L P Park; D S Stein; J P Phair; J W Mellors; R Detels; A J Saah
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391

View more
  12 in total

Review 1.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

2.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

3.  M-tropic HIV envelope protein gp120 exhibits a different neuropathological profile than T-tropic gp120 in rat striatum.

Authors:  Alessia Bachis; Maria I Cruz; Italo Mocchetti
Journal:  Eur J Neurosci       Date:  2010-07-28       Impact factor: 3.386

Review 4.  When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration?

Authors:  Italo Mocchetti; Lee A Campbell; G Jean Harry; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-15       Impact factor: 4.147

Review 5.  HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments.

Authors:  Adonira Saro; Zhaolin Gao; Piniel Alphayo Kambey; Paul Pielnaa; Dama Faniriantsoa Henrio Marcellin; Aixiang Luo; Ruping Zheng; Zhongjun Huang; Lvshuang Liao; Mingxuan Zhao; Liangpeng Suo; Shuang Lu; Min Li; Deyang Cai; Dan Chen; Haiyang Yu; Jufang Huang
Journal:  Cell Mol Neurobiol       Date:  2021-09-25       Impact factor: 4.231

6.  Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity.

Authors:  Lara Buscemi; David Ramonet; Jonathan D Geiger
Journal:  Neurobiol Dis       Date:  2007-03-20       Impact factor: 5.996

7.  CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease.

Authors:  Mika Shimoji; Fernando Pagan; Edward B Healton; Italo Mocchetti
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

8.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

Review 9.  Purinergic signaling in infectious diseases of the central nervous system.

Authors:  Vinícius Santos Alves; Raíssa Leite-Aguiar; Joyce Pereira da Silva; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Brain Behav Immun       Date:  2020-07-24       Impact factor: 7.217

Review 10.  Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans.

Authors:  Marc Desforges; Alain Le Coupanec; Elodie Brison; Mathieu Meessen-Pinard; Pierre J Talbot
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.